Prime Editing Makes Therapeutic T Cells Controllable Under Immunosuppression

Company WEHI (with Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and Westmead collaborators) Event Type Published Research (Peer-Reviewed, Preclinical Platform Study) Modality Multiplex prime editing (disease correction plus drug-resistance engineering) Asset Multiplex prime-editing framework for drug-controllable therapeutic T cells (research-stage, not a named clinical asset)…